Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ASX listed PharmAust will be conducting the second phase of its dog-lymphatic cancer trial at University of Melbourne’s U-Vet Werribee Animal Hospital
  • Due to the collaborative agreement, U-Vet’s Head of Small Animal Medicine Dr Claire Cannon will oversee the trial — who has experience in private practice, the University of Melbourne and universities in Minnesota and Tennessee
  • Dr Claire Cannon will also contribute to the participant selection process which is currently underway
  • The U-Vet Animal Hospital recently underwent a $63 million redevelopment — part of a campus wide $100 million overhaul

Good news for our furry friends today, as ASX listed PharmAust teams up with University of Melbourne’s animal hospital for a dog-cancer trial.

The phase-II trial has been in the making for quite some time now, but today’s latest development of the collegiate level collaboration puts extra firepower on the line.

PharmAust will now be conducting the trial at University of Melbourne’s U-Vet Werribee Animal Hospital.

Due to the collaborative agreement, U-Vet’s Head of Small Animal Medicine Dr Claire Cannon will oversee the trial.

Dr Claire has experience across the University of Melbourne, University of Minnesota and University of Tennessee. She has also accrued experience from private practices in Australia and the U.K.

“PharmAust is very pleased to be working with Dr Cannon and her team at U-Vet and the University of Melbourne,” PharmAust Chief Scientific Officer Dr Richard Mollard said.

The U-Vet Werribee Animal Hospital
Image sourced from University of Melbourne

Dr Claire Cannon will also give her guidance to the recruitment of the furry-tailed friends, which is currently being finalised.

“PharmAust is looking forward to sharing the data generated from the trial at U-Vet and other sites when they become available,” Dr Richard added.

The PharmAust trial will focus specifically on lymphatic cancer in the canine participants.

At the end of 2018, the U-Vet Animal Hospital completed a $63 million makeover. The transformation was part of a $100 million overhaul for the University’s Parkville campus.

The animal hospital redevelopment aimed to ‘enhance the experience for clients and pets’.

“The new facilities will provide our staff and students with increased access to cutting-edge equipment and purpose-built spaces,” Faculty of Veterinary Dean Professor Fazakerley said in late 2017.

The overhauled facility included new teaching and learning spaces in a five-storey building.

The new animal hospital also included café, gardens, and increased parking and accessibility.

Despite the positive announcement, share prices in PharmAust are stagnant today — trading at 14.5 cents apiece. The company’s market cap is currently valued at $40.63 million.

PAA by the numbers
More From The Market Herald
Dimerix (ASX:DXB) - Managing Director and CEO, Nina Webster

" Dimerix (ASX:DXB) expands DMX-200 study into Australia

Dimerix (DXB) has entered an agreement with the NHMRC Clinical Trials Centre at the University of Sydney to expand the CLARITY 2.

" ACCC scrambles to halt Virtus Health’s (ASX:VRT) purchase of Healius (ASX:HLS) IVF clinics

The ACCC has taken “a significant step” as it seeks an urgent injunction to stop Virtus Health’s (VRT) proposed acquisition of Adora Fertility
IDT Australia (ASX:IDT) - Chair, Alan Fisher

" IDT Australia (ASX:IDT) signs manufacturing deal with Monash University

IDT Australia (IDT) has entered a master services agreement and services order with Monash University.
Prescient Therapeutics (PTX) - CEO and MD, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) to present new OmniCAR data at conference

Prescient Therapeutics (PTX) will present new results for its OmniCAR drug at the Cell & Gene Meeting on Mesa in California.